Editas Medicine (EDIT) Short term Debt (2024 - 2025)
Editas Medicine (EDIT) reported Short term Debt of $5.0 million for Q4 2025, little changed year-over-year from $5.0 million in Q4 2024, and little changed quarter-over-quarter from $5.0 million in Q3 2025.
Editas Medicine (EDIT) Short term Debt (2024 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 2 years of Short term Debt data on file, last reported at $5.0 million in Q4 2025.
- Short term Debt for Q4 2025 came in at $5.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.0 million (changed 0.0% YoY), and the FY2025 annual result was $5.0 million, changed 0.0% from the prior year.
- Short term Debt was little changed at $5.0 million in Q4 2025 per EDIT's latest filing, from $5.0 million in the prior quarter.
- Over five years, Short term Debt peaked at $5.0 million in Q4 2024 and troughed at $5.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |